GT Medical Technologies raises $100.0M Series E (United States, Jun 2026)
$100.0M
$100M Series EGenerated social card
Headline
GT Medical Technologies Raises $100M Series E to Advance Brain Tumour Therapy - Ventureburn
About
GT Medical Technologies develops innovative treatments for brain tumor patients, focusing on improving survival outcomes and quality of life. Their flagship product, GammaTile therapy, delivers immediate targeted radiation at the tumor site during surgery, aiming to reduce tumor regrowth and limit exposure to healthy brain tissue.
Article summary
GT Medical Technologies Raises $100M Series E to Advance Brain Tumour Therapy Ventureburn
Investors · 6
4 hiddenRelated rounds
| Jun 29, 2026 | Nebulock | $25.0M | — | United States |
| Jun 29, 2026 | Archimede | $1.6M | Seed | United States |
| Jun 29, 2026 | Omen AI | $31.0M | — | United States |
| Jun 29, 2026 | Techdollar | $3.0M | Pre-seed | United States |